Cyclo G6® Laser

For MicroPulse transscleral laser therapy and Continuous-Wave Cyclophotocoagulation

Ophthalmologists in more than 80 countries use the Cyclo G6 Laser to treat a wide range of glaucoma cases. The Iridex Cyclo G6 Laser is a semiconductor diode laser that delivers true continuous wave infrared (810 nm) laser light for glaucoma applications. Nearly 250,000 procedures have been performed in over 80 countries with the laser and its three probes (MicroPulse P3, G-Probe, and G-Probe Illuminate Delivery Devices).

With continuous-wave and MicroPulse treatment modes
Countdown Timer with audible/voice confirmations
Programmable user presets for up to 10 individual presets
Optional power-adjust wireless footswitch (wired footswitch included)
Color LCD Touchscreen interface
Backlit control knobs and Treat/Standby button
Optional Remote Control (high viewing angle, color LCD touchscreen)


Wavelength 810 nm infrared
Weight 4.8 kg (10.5 lb)
Dimensions 27 cm x 29.5 cm x 19.7 cm (10.6” W x 11.6” D x 7.8” H)
Connector Type SmartProbe RFID with Laser Parameter Memory
Electrical 100-240 VAC, 50/60 Hz, <0.8 A
Cooling Air cooled
Exposure Duration CW-Pulse: 10 ms – 9000 ms in 606 increments and continuous pulse up to 60 seconds
Exposure Interval CW-Pulse: 10 – 3000 ms in 598 increments and One Pulse
MicroPulse® Duration MicroPulse: 0.05-1.0 ms in 19 increments
MicroPulse Interval MicroPulse: 1.0-10.0 ms in 90 increments
MicroPulse Duty Cycle Continuously adjustable from 0.5%-50%, and preset selections of 5%, 10%, and 15% duty cycles
Aiming Beam Diode laser, 635 nm nominal
Treatment Power 50-3000 mW, depending on delivery device

Order Information

The product number for the Cyclo G6 Laser is CYCLO-G6-SYSTEM. To order, speak with your local sales representative or email us at

I have been using the Cyclo G6 Laser with the MicroPulse P3 probe in my practice for more than 2 years. MicroPulse mode has proven to be an efficacious choice for many of my glaucoma patients, with a significant reduction in pressure and medication use for most. I have found that after MP-TSCPC procedures, my patients experience less pain and less post-procedural inflammation than after traditional CPC.Jonathan S. Myers, MD – Philadelphia, PA USA
Since 2016, I have loved having Iridex‘s Cyclo G6 Laser in my surgical toolbox for many types of glaucoma, including those in late stage and refractory stages. I am a big fan because this can often save someone from incisional surgery. Of course, selecting the right patient is key to ensure good outcomes and minimal side effectsMonisha Vora, MD – Philadelphia, PA USA
I have been impressed that the MicroPulse P3 therapy with the Cyclo G6 Glaucoma Laser can deliver pressure lowering in a broad range of glaucomas, including mild and moderate patients who I want to free from the adverse effects of drops.Rolando Toyos, MD – Nashville, TN USA

Featured Blog Post

SLx Laser Donated to Ivory Coast

SLx Laser Donated to Ivory Coast

At Iridex, we feel passionate about partnering with physicians and organizations that share our mission to fight blindness, improve quality of care, and make a difference in patients’ lives. Recently, through our Iridex Cares program, we partnered with Dr. Andrew Toren (Canada) and Salient Medical Solutions (our distributor in Canada) to bring our laser technology

Read More

Recent News

A menu of glaucoma treatments includes options to fit all scenarios

An article by Michael C. Giovingo, MD, discusses multiple treatment options glaucoma, surgeons have a number of options at their disposal, including MicroPulse Laser Trabeculoplasty (MLT), LicroPulse TLT, and Continuous-Wave TSCPC.

Read More

Transscleral laser therapy device simplifies procedure

MicroPulse Transscleral Laser Therapy (MicroPulse TLT) is a nonincisional procedure that substantially reduces IOP for a broad range of glaucoma patients. Patient-friendly, safe, and effective, MicroPulse TLT is my preferred nonincisional procedure for glaucoma patients before proceeding to surgical interventions to potentially reduce the number of drop therapies or address drop failure.

Read More